Vitamin D status was not associated with 'one-year' progression of coronary artery disease, assessed by coronary angiography in statin-treated patients. (29th August 2020)

• Record Type: Journal Article
• Authors: Degerud, Eirik; Løland, Kjetil H; Nygård, Ottar; Midttun, Øivind; Ueland, Per M; Seifert, Reinhard; Strand, Elin; Bleie, Øivind; Dierkes, Jutta
• Is Part Of: European journal of preventive cardiology. Volume 22:Number 5(2015)
• Page Start: 594
• Page End: 602
• Publication Date: 2020-08-29
• Subjects: Vitamin D -- 25-hydroxyvitamin D -- calcifediol -- coronary artery disease -- atherosclerosis -- disease progression -- coronary angiography; Cardiovascular system -- Diseases -- Prevention -- Periodicals; Cardiac patients -- Rehabilitation -- Periodicals; 616.12
• DOI: 10.1177/2047487314522137
• Languages: English
• ISSNs: 2047-4873

Abstract

Abstract: Background: Low vitamin D status is associated with increased risk of cardiovascular disease and may be involved in atherosclerosis. Our aim was to assess the association between vitamin D status and the progression of coronary artery disease (CAD). Methods and Results: We measured 25-hydroxyvitamin D3 (25OHD3) by liquid chromatography tandem mass spectrometry (LC-MS/MS) in plasma from 348 participants with established CAD (84% males, mean ± standard deviation (SD) age 60 ± 10 years) of the Western Norway B-vitamin Intervention Trial (WENBIT, 1999–2006). The patients underwent invasive coronary angiography (CA) and percutaneous coronary intervention at baseline and a second CA after 302 ± 79 days of follow-up. From the angiograms, minimal lumen diameter (MLD) and diameter stenosis (DS) of atherosclerotic lesions were obtained. Significant CAD in non-intervened vessels was found in 309 coronary arteries from 183 participants either at baseline and/or at follow-up. To assess the association between levels of 25OHD3 and CAD progression in non-intervened vessels, we applied a linear quantile fitted mixed effects model with MLD or DS measured at follow-up as a function of continuous 25OHD3 concentrations. There were no statistically significant associations between plasma 25OHD3 concentrations (median: 63.9, 95% confidence interval (CI): 48.1–78.5 nmol/l) measured at baseline and the follow-up measures of either MLD (estimated effect per 10 nmol/l increase of 25OHD3 and 95% CI: –0.015 (−0.032–0.002) mm, p = 0.088) or DS (0.225 (−0.354–0.804) percentage points, p = 0.444). Multivariate adjustment did not alter these results. Conclusion: Plasma 25OHD3 levels were not associated with 'one-year' progression of CAD, assessed by CA in statin-treated patients.